The FDA Has Awarded Orphan Drug Designation to a Therapy for Complications After Haematopoietic Cell Transplantation
The United States Food and Drug Administration has awarded Orphan Drug Designation to an experimental PLX cell therapy (called PLX-R18) as a treatment for graft failure and incomplete haematopoietic recovery…